The therapeutic potential of targeting the tumor vascular supply is now widely recognized.
Intense research and development activity has resulted in a variety of investigational agents, a …

Selective induction of vascular damage within tumors represents an emerging approach to
cancer treatment. Histological studies have shown that several tubulin-binding agents can …

Background Individual patient data from two randomised trials comparing neoadjuvant
chemotherapy with upfront debulking surgery in advanced tubo-ovarian cancer were analysed to …

Purpose: To determine efficacy and toxicity of two pemetrexed-based regimens in chemonaive
patients with locally advanced or metastatic non–small cell lung cancer. Experimental …

Background Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line
chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a …

Objectives We evaluated four different treatment regimens for advanced-stage mucinous
epithelial ovarian cancer. Methods We conducted a multicenter randomized factorial trial (UK …

Introduction Pemetrexed has established efficacy, and is the backbone for chemotherapy in
patients with malignant pleural mesothelioma (MPM). An International Expanded Access …

Background Platinum-based neoadjuvant chemotherapy followed by delayed primary
surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage …

Background The ICON8 study reported no significant improvement in progression-free
survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly …

Background: Phase III studies suggest that non-small-cell lung cancer (NSCLC) patients
treated with cisplatin–docetaxel may have higher response rates and better survival compared …